University of Illinois Cancer Center
V

HR+/HER2- Early Breast Cancer: Risk Assessment and Treatment Updates

By University of Illinois Cancer Center FEATURING V.K. Gadi
By University of Illinois Cancer Center FEATURING V.K. Gadi
136 views
November 19, 2024
Comments 0
Login to view comments. Click here to Login

Featured Video

03:38
Lilly Medical Affairs

SERDS: Relevance and Role in Current & Future Treatments for HR+…

Feat. K. Jhaveri

Featured Video

03:57
Lilly Medical Affairs

Resistance Mechanisms to ET, Including ESR1 Mutations in HR+, HER2- …

Feat. K. Jhaveri

Related Videos

25:08

ASCO® 2024 Breast Cancer Highlights - Monday Morning Practice

2024 ASCO® Annual Meeting Insights Hub

S. Tolaney, H. Rugo

4.2K views
12:14

ASCO® 2024 Breast Cancer Highlights: Top 5 Abstracts - DESTINY-Breas…

2024 ASCO® Annual Meeting Insights Hub

P. Tarantino

2.2K views
06:39

FDA Approval Clinical Implications: Inavolisib With Palbociclib and …

Memorial Sloan Kettering Cancer Center

K. Jhaveri

617 views
10:53

Integrating Oral Therapy for Patients With HR+/HER2- Early Stage BC

Kirollos Hanna

2.2K views
17:12

Strategies for Managing Toxicities of Oral Oncolytics in Breast Canc…

UNC Lineberger Comprehensive Cancer Center

A. Faso, B. Patel, K. Chen

1.5K views
14:52

ESMO 2024 Summary: Top 5 Breast Cancer Abstracts - NATALEE, DESTINY-…

2024 ESMO Annual Meeting Insights Hub

P. Tarantino

771 views
09:55

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future Hold?"

2024 ASCO® Annual Meeting Insights Hub

E. Hamilton

1.5K views
02:58
Lilly Medical Affairs

A Heterogenous Disease with Varied Clinical Outcomes: HR+/HER2- MBC

Feat. J. O’Shaughnessy
20:32

ESMO 2024 Summary: mBC Panel Discussion on Key Studies - DESTINY-Bre…

2024 ESMO Annual Meeting Insights Hub

S. Tolaney, H. Rugo

542 views
38:49

ESMO 2024 Summary: eBC Panel Discussion on Key Studies - KEYNOTE-522…

2024 ESMO Annual Meeting Insights Hub

S. Tolaney, H. Rugo

531 views
09:12

ESMO 2024 Summary: Breast Cancer Highlights - KEYNOTE-522, NATALEE, …

2024 ESMO Annual Meeting Insights Hub

V. Kaklamani

510 views
07:23

Advanced Stage HR+ BC: Fine-Tuning Sequential Endocrine and Targeted…

Total Health

R. O'Regan

1.4K views
21:34

The 2023 ASCO®/CAP Guideline Update on HER2 Testing/Classification: …

Shabnam Jaffer

702 views
06:51

New

SABCS 2024 Noteworthy Abstracts in Metastatic Breast Cancer

Sara Tolaney

H. Rugo

302 views
20:25

ESMO 2024 Summary: Highlights in mBC

2024 ESMO Annual Meeting Insights Hub

G. Bianchini

504 views
15:57

New

SABCS 2024 Noteworthy Abstracts in Early Breast Cancer

Sara Tolaney

H. Rugo

358 views
03:57
Lilly Medical Affairs

Resistance Mechanisms to ET, Including ESR1 Mutations in HR+, HER2- …

Feat. K. Jhaveri
12:38

NATALEE Trial Impact on eBC: Ribociclib + ET as Adjuvant Treatment i…

Jan-Willem Henning

431 views
16:19

Optimizing Adjuvant Treatment in High-Risk HR+/HER2- eBC: Patient Se…

Wassim Mchayleh

884 views
26:06

Perspectives on the Effects of Time Toxicity in Breast Cancer Treatm…

Kathryn Post

J. Hutchinson

619 views
AUTOPLAY